Many patients diagnosed with rheumatism for the first time are very troubled by this problem. Taking time off work to run to the hospital and line up to see a doctor is a hassle, but for rheumatism, more tests are unavoidable because the conditions of individual rheumatism patients vary greatly and multiple tests are needed to cater for individualized treatment. Rheumatology examinations can be divided into the following categories: biochemical indicators that measure nucleic acids, proteins, lipids, carbohydrates, metabolites, biomolecules in the blood, synovial fluid, other body fluids and tissues. These are indicators that observe physiology, pathology, and response to drug therapy through various objective quantitative measurements. Imaging, including MRI, positron emission computed tomography (PET-CT) and ultrasound, can provide a visual representation of disease activity and efficacy in anatomical structures to aid in disease diagnosis and efficacy assessment. Imaging biomarkers are more closely related to disease symptoms and signs than biochemical indicators. Finally, there is the classic symptom assessment of disease, such as joint counts and pain scores. Because clinical biomarkers are usually not precise and objective enough, they do not provide sufficiently comprehensive and precise guidance for treatment options. In other words, the diagnostic criteria for all rheumatologic diseases currently require clarification based on clinical symptoms, biochemical indicators and even imaging. These tests are necessary for precision medicine; they allow the disease to be diagnosed earlier and can allow for more precise treatment. For example, it is possible to assess whether the disease is serious, whether there is a relapse, whether it is in remission, whether the current treatment regimen needs to be interrupted or improved, and to assess the predicted toxic effects of drugs. Thus a rheumatology department with a well-developed platform for evaluating disease can improve diagnosis and allow patients to make fewer trips to the hospital, while helping patients to understand the efficacy and side effects of medications, so that ineffectiveness or side effects can promptly change the treatment plan and reduce long-term medical costs for patients. Although more and more tests can now be used for precision medicine for rheumatic diseases, there have been difficulties and obstacles to the development of this area. For example, the level of technology has not yet reached the point where only one test can be developed to diagnose and guide treatment for a disease. The latest generation of tests are now geared toward developing indicators for genetic and immune inflammatory factor-targeted therapy. It is expected that in the near future, biomarker tests will be used to predict the likelihood of disease onset in very early or even suboptimal states, hopefully preventing the onset of disease earlier.